Vergleich

Deferoxamine (mesylate)

ArtNr CS-4479-100mg
Hersteller ChemScene
Menge 100mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 138-14-7
Lieferbar
Alternative Names
Desferrioxamine B mesylate; DFOM
CAS
138-14-7
Purity
>98%
Formula
C26H52N6O11S
MWt
656.79
Solubility
H2O : >= 33 mg/mL (50.24 mM)
Clinical Information
Launched
Pathway
Neuronal Signaling; Autophagy; Autophagy
Target
Amyloid-beta; Autophagy; Mitophagy
Biological Activity
Deferoxamine mesylate is an iron chelator, and effectively reduces oxidative stress and neuronal death. In Vitro: Deferoxamine treatment significantly increases HIF-1alpha binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1alpha biological function through scavenging oxygen free radicals[1]. Deferoxamine (5 uM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 uM and 100 uM deferoxamine. Deferoxamine (5 uM-100 uM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs[3]. Deferoxamine (30, 60, 120?uM) shows lower expression of HIF-1alpha in a concentration dependent way in AdMSCs[4]. In Vivo: Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan�s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental[1]. Ten uL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice[2]. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Abeta40 and Abeta42. Both pGSK3beta and beta-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice[5].

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen